Allergan Opioid Settlement Leaves Teva Alone in N.Y. Trial (2)

Dec. 8, 2021, 11:44 PM

Allergan Plc agreed to pay $200 million to settle a New York lawsuit over the marketing of highly addictive opioid painkillers, leaving Teva Pharmaceutical Industries Ltd. as the lone defendant remaining in a public-nuisance trial that is wrapping up after six months of testimony.

Allergan, acquired by rival drugmaker AbbVie Inc. last year, will pay the money by 2022 and the majority of it is slated to help replenish drug-treatment and social-service budgets depleted by the opioid epidemic, New York Attorney General Letitia James said in a statement. Allergan also agreed earlier to stop making opioids.

“While no amount of ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.